AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2874128 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 60
Study 2874128 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam
Number of subjects: 60
Study 2874128 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 60
Study 31101513 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-treatment with buspirone and AAPDs
Number of subjects: 200
Study 31101513 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with AAPDs
Number of subjects: 200
Study 28239942 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended CBT (E-CBT)
Number of subjects: 219
Study 28239942 — intervention group
Group type: COMPARATOR
Intervention: Non-extended CBT (no additional CBT sessions)
Number of subjects: 219
Study 25662346 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofilament Test
Number of subjects: 105
Study 25662346 — intervention group
Group type: EXPERIMENTAL
Intervention: Motricity Index
Number of subjects: 105
Study 25662346 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine‐Hole Peg Test (NHPT)
Number of subjects: 105
Study 25662346 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Integration Questionnaire
Number of subjects: 105
Study 23159547 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7141
Study 23159547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7141
Study 21917244 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit causal inferences (implied by subsequent footage)
Number of subjects: 0
Study 21917244 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of the resulting flight of the ball with irrelevant video
Number of subjects: 0
Study 21917244 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrambling event segments
Number of subjects: 0
Study 21917244 — intervention group
Group type: COMPARATOR
Intervention: Different causal implication conditions
Number of subjects: 0
Study 19187641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid fluid expansion (Group I, n = 36) at a rate of 10-15 ml x kg(‐1) x h(‐1)
Number of subjects: 76
Study 19187641 — intervention group
Group type: COMPARATOR
Intervention: Controlled fluid expansion (Group II, n = 40) at a rate of 5-10 ml x kg(‐1) x h(‐1)
Number of subjects: 76
Study 19187641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid fluid expansion (Group I)
Number of subjects: 76
Study 19187641 — intervention group
Group type: COMPARATOR
Intervention: Controlled fluid expansion (Group II)
Number of subjects: 76
Study 17202428 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback display of movement; adaptation to three different rotations of feedback display; sequential adaptation process.
Number of subjects: 0
Study 14722035 — intervention group
Group type: EXPERIMENTAL
Intervention: DPPE plus DOX
Number of subjects: 256
Study 14722035 — intervention group
Group type: COMPARATOR
Intervention: DOX
Number of subjects: 256
Study 11573597 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 1 mg kg(‐1)
Number of subjects: 80
Study 11573597 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.15 mg kg(‐1)
Number of subjects: 80
Study 11573597 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 80
Study 9756242 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (all round activities) 3-4 times a week for six months
Number of subjects: 229
Study 9756242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer training 3-4 times a week for six months
Number of subjects: 229
Study 9756242 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 229
Study 7848006 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic use of eubiotics (bifidumbacterin and lactobacterin)
Number of subjects: 44
Study 2693499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 0
Study 2693499 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 30295168 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Contact Casting (TCC)
Number of subjects: 31
Study 30295168 — intervention group
Group type: COMPARATOR
Intervention: Traditional Dressing (TD)
Number of subjects: 31
Study 27974308 — intervention group
Group type: EXPERIMENTAL
Intervention: Problematic eating attitudes (ChEAT scores ≥85th percentile)
Number of subjects: 13557
Study 27974308 — intervention group
Group type: EXPERIMENTAL
Intervention: Problematic eating attitudes (ChEAT scores ≥85th percentile) after controlling for BMI at age 6.5 y
Number of subjects: 13557
Study 24002121 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily for 9 months
Number of subjects: 76
Study 24002121 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine 10 mg daily for 9 months
Number of subjects: 76
Study 24251286 — intervention group
Group type: EXPERIMENTAL
Intervention: Education of husbands about cesarean and vaginal delivery
Number of subjects: 88
Study 24251286 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education provided)
Number of subjects: 88
Study 21124833 — intervention group
Group type: EXPERIMENTAL
Intervention: Grey dots task (distraction with irrelevant grey dot)
Number of subjects: 0
Study 21124833 — intervention group
Group type: EXPERIMENTAL
Intervention: Red dot task (detection of color change in grey dot)
Number of subjects: 0
Study 21124833 — intervention group
Group type: COMPARATOR
Intervention: Standard AB task (identifying two target letters)
Number of subjects: 0
Study 21124833 — intervention group
Group type: EXPERIMENTAL
Intervention: Red dot task
Number of subjects: 0
Study 18067498 — intervention group
Group type: EXPERIMENTAL
Intervention: New brochure addressing common donor concerns and suggesting specific coping strategies
Number of subjects: 0
Study 18067498 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard blood center brochure
Number of subjects: 0
Study 18067498 — intervention group
Group type: COMPARATOR
Intervention: Control brochure on healthy eating and exercise
Number of subjects: 0
Study 17175797 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous sural nerve grafts
Number of subjects: 50
Study 17175797 — intervention group
Group type: COMPARATOR
Intervention: Vein conduit with interposition of a posterior interosseous nerve segment
Number of subjects: 50
Study 17175797 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 14534392 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced gender- and culturally specific intervention conditions
Number of subjects: 71
Study 14534392 — intervention group
Group type: COMPARATOR
Intervention: NIDA standard condition
Number of subjects: 71
Study 10779449 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (100 or 500 U/kg of body weight given intravenously)
Number of subjects: 30
Study 10779449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8622077 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunoguided surgery (RIGS) using iodine 125‐labeled monoclonal antibodies (MAbs) B72.3 (anti‐TAG72)
Number of subjects: 21
Study 8622077 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunoguided surgery (RIGS) using iodine 125‐labeled monoclonal antibodies (MAbs) FO23C5 (anti‐carcinoembryonic antigen [CEA])
Number of subjects: 21
Study 1548650 — intervention group
Group type: COMPARATOR
Intervention: Standard course
Number of subjects: 35
Study 1548650 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional seminar on otoscopy
Number of subjects: 35
Study 3914702 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg/d
Number of subjects: 19
Study 3914702 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice a day
Number of subjects: 19
Study 30855399 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 351
Study 28873106 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid 30% peel
Number of subjects: 12
Study 28873106 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic broadband light (PBBL)
Number of subjects: 12
Study 27087092 — intervention group
Group type: EXPERIMENTAL
Intervention: TEST 500 mg
Number of subjects: 12
Study 27087092 — intervention group
Group type: COMPARATOR
Intervention: REF® 500 mg
Number of subjects: 12
Study 23793487 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers and Babies Course (MB) intervention
Number of subjects: 78
Study 23793487 — intervention group
Group type: COMPARATOR
Intervention: Usual home visiting services (control)
Number of subjects: 78
Study 22318492 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral desensitization protocol enabled with omalizumab (anti-IgE monoclonal antibodies)
Number of subjects: 0
Study 19514438 — intervention group
Group type: EXPERIMENTAL
Intervention: PEA with intramuscular ketorolac
Number of subjects: 100
Study 19514438 — intervention group
Group type: EXPERIMENTAL
Intervention: PEA with intramuscular ketorolac and intravenous paracetamol
Number of subjects: 100
Study 19514438 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural analgesia (PEA)
Number of subjects: 100
Study 18161500 — intervention group
Group type: EXPERIMENTAL
Intervention: Superordinate concepts
Number of subjects: 0
Study 18161500 — intervention group
Group type: COMPARATOR
Intervention: Basic-level concepts
Number of subjects: 0
Study 14707874 — intervention group
Group type: EXPERIMENTAL
Intervention: Local diagnosis by pathologists at 22 participating institutions
Number of subjects: 2004
Study 14707874 — intervention group
Group type: COMPARATOR
Intervention: Central diagnosis by study pathologists
Number of subjects: 2004
Study 14707874 — intervention group
Group type: COMPARATOR
Intervention: Open surgical biopsies
Number of subjects: 2004
Study 11410120 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral combined hormone replacement therapy (HRT)
Number of subjects: 37
Study 11410120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9229276 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal communication plus PDQ Patient Information File (PIF)
Number of subjects: 0
Study 9229276 — intervention group
Group type: COMPARATOR
Intervention: Verbal communication only
Number of subjects: 0
Study 8213507 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 0
Study 3679646 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation at 50 Hz
Number of subjects: 0
Study 3679646 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation at 2000 Hz
Number of subjects: 0
Study 3679646 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation at 50 Hz and 2000 Hz
Number of subjects: 0
Study 30690550 — intervention group
Group type: EXPERIMENTAL
Intervention: SIPsmartER intervention
Number of subjects: 117
Study 29660936 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ACE‐1 levels
Number of subjects: 56
Study 27857014 — intervention group
Group type: COMPARATOR
Intervention: Self-efficacy promoting vestibular rehabilitation (S-VR) after 4 weeks
Number of subjects: 0
Study 27857014 — intervention group
Group type: COMPARATOR
Intervention: Self-efficacy promoting vestibular rehabilitation (S-VR) after 8 weeks
Number of subjects: 0
Study 24625934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 120
Study 24625934 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 120
Study 24625934 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 100 mg
Number of subjects: 120
Study 23084768 — intervention group
Group type: EXPERIMENTAL
Intervention: Block autogenous bone
Number of subjects: 17
Study 23084768 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate graft
Number of subjects: 17
Study 20678235 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried pre‐clinical disability screening tool
Number of subjects: 471
Study 20678235 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical models
Number of subjects: 471
Study 18261392 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy (Acenocoumarol)
Number of subjects: 49
Study 18261392 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 49
Study 16760270 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/day
Number of subjects: 448
Study 16760270 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/day
Number of subjects: 448
Study 12829890 — intervention group
Group type: COMPARATOR
Intervention: Tac and steroids (control)
Number of subjects: 104
Study 12829890 — intervention group
Group type: EXPERIMENTAL
Intervention: TacSRL0.5 (0.5 mg SRL)
Number of subjects: 104
Study 12829890 — intervention group
Group type: EXPERIMENTAL
Intervention: TacSRL1 (1 mg SRL)
Number of subjects: 104
Study 12829890 — intervention group
Group type: EXPERIMENTAL
Intervention: TacSRL2 (2 mg SRL)
Number of subjects: 104
Study 10880788 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold transcranial magnetic stimulation (TMS) delivered at 90% of resting motor evoked potential (MEP) threshold
Number of subjects: 0
Study 10880788 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming TMS with the go-signal
Number of subjects: 0
Study 10880788 — intervention group
Group type: EXPERIMENTAL
Intervention: Occipital priming stimulation
Number of subjects: 0
Study 10880788 — intervention group
Group type: EXPERIMENTAL
Intervention: M1 stimulation
Number of subjects: 0
Study 10880788 — intervention group
Group type: COMPARATOR
Intervention: Control group (normals)
Number of subjects: 0
Study 9048263 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 22
Study 9048263 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 22
Study 9048263 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 22
Study 9048263 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 22
Study 9048263 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive hyperaemia
Number of subjects: 22
Study 1619073 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately potent corticosteroids
Number of subjects: 66
Study 1619073 — intervention group
Group type: EXPERIMENTAL
Intervention: Very potent corticosteroids
Number of subjects: 66
Study 1619073 — intervention group
Group type: COMPARATOR
Intervention: Moderately potent corticosteroids with propylene glycol 25%
Number of subjects: 66
Study 6542402 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg single dose)
Number of subjects: 736
Study 6542402 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated chemotherapy, sanitation improvement, and health education
Number of subjects: 736
Study 6542402 — intervention group
Group type: COMPARATOR
Intervention: Control (only chemotherapy)
Number of subjects: 736
Study 6542402 — intervention group
Group type: EXPERIMENTAL
Intervention: Test villages
Number of subjects: 736
Study 6542402 — intervention group
Group type: COMPARATOR
Intervention: Control village
Number of subjects: 736
Study 31914451 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASP)
Number of subjects: 207
Study 31914451 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel (ASP-CLO)
Number of subjects: 207
Study 28600597 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 132
Study 28600597 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 132
Study 25903091 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma alkylresorcinol concentrations
Number of subjects: 182
Study 25766724 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 0
Study 25766724 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 0
Study 22900932 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening intervention (fasting plasma glucose measurement and referral to GP if FPG ≥ 6.1 mmol/L)
Number of subjects: 10609
Study 22900932 — intervention group
Group type: COMPARATOR
Intervention: Control group (received written healthy lifestyle information)
Number of subjects: 10609
Study 20733132 — intervention group
Group type: EXPERIMENTAL
Intervention: TCG (carboplatin plus paclitaxel plus gemcitabine)
Number of subjects: 1742
Study 20733132 — intervention group
Group type: COMPARATOR
Intervention: TC (carboplatin plus paclitaxel)
Number of subjects: 1742
Study 18937623 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac formulations (sodium lotion, lecithin or epolamine gel, patch or plaster)
Number of subjects: 0
Study 18937623 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac formulations
Number of subjects: 0
Study 15769238 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of performance information with small numbers (e.g., absence rates of 2% vs. 5%)
Number of subjects: 0
Study 15769238 — intervention group
Group type: COMPARATOR
Intervention: Presentation of performance information with large numbers (e.g., attendance rates of 98% vs. 95%)
Number of subjects: 0
Study 15769238 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing the presentation format of performance information
Number of subjects: 0
Study 12360152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan
Number of subjects: 193
Study 12360152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 10094298 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-sensory stimulation (auditory, tactile, visual, and vestibular intervention) for 15 minutes, twice a day, five days a week, for four weeks during hospitalization
Number of subjects: 30
Study 10094298 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 7538547 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with zidovudine and L‐697,661
Number of subjects: 119
Study 7538547 — intervention group
Group type: COMPARATOR
Intervention: L‐697,661 alone
Number of subjects: 119
Study 7538547 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 119
Study 2405619 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 2332
Study 2405619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2332
Study 2405619 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and nonsmoking
Number of subjects: 2332
Study 2405619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 2332
Study 6631566 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g orally once a day, five times a week for 20 weeks)
Number of subjects: 50
Study 6631566 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (60 mg as zinc gluconate once a day, five times a week for eight weeks)
Number of subjects: 50
Study 6631566 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched control group)
Number of subjects: 50
Study 30316907 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OCP) - 35μg of ethinylestradiol plus 2mg of cyproterone acetate for 6 cycles (28 days each)
Number of subjects: 101
Study 30316907 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin - 500mg administered twice daily for 6 months
Number of subjects: 101
Study 30316907 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo pills during OCP treatment)
Number of subjects: 101
Study 28277151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training (CWMT) followed by Behavioral Parent Training (BPT)
Number of subjects: 85
Study 28277151 — intervention group
Group type: COMPARATOR
Intervention: Placebo version of CWMT followed by Behavioral Parent Training (BPT)
Number of subjects: 85
Study 26822324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 282
Study 26822324 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 282
Study 23597077 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 20
Study 23597077 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 20
Study 23597077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22333484 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 75
Study 22333484 — intervention group
Group type: EXPERIMENTAL
Intervention: atazanavir/ritonavir (ATV/r)
Number of subjects: 75
Study 19823919 — intervention group
Group type: EXPERIMENTAL
Intervention: Animation-based video education
Number of subjects: 242
Study 19823919 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 242
Study 16887862 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID treatment
Number of subjects: 0
Study 16849624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziconotide administered intrathecally via continuous infusion
Number of subjects: 0
Study 16849624 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 12820279 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint piecewise exponential joint model
Number of subjects: 0
Study 12820279 — intervention group
Group type: COMPARATOR
Intervention: Standard proportional hazards model
Number of subjects: 0
Study 11303962 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhetic acid (GA) ingestion
Number of subjects: 0
Study 11303962 — intervention group
Group type: EXPERIMENTAL
Intervention: Human PBPK model
Number of subjects: 0
Study 11303962 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated licorice consumption
Number of subjects: 0
Study 8784096 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (2 IU/m2 day)
Number of subjects: 29
Study 1732485 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oral administration of a combination of rapid- and slow-release diclofenac (Voltaren)
Number of subjects: 0
Study 1732485 — intervention group
Group type: COMPARATOR
Intervention: Combination of intramuscular diclofenac and an oral depot formula
Number of subjects: 0
Study 6370978 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine (100-150 mg/day)
Number of subjects: 36
Study 6370978 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (100-150 mg/day)
Number of subjects: 36
Study 29265423 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 0